Toxic epidermal necrolysis and Stevens-Johnson syndrome

Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes. Both are rare, with TEN and SJS affecting approximately 1or 2/1,000,000 annually, and are considered medical emergencies as they are potentially fatal. They are characterized by mucocutaneous tenderness and typically hemorrhagic erosions, erythema and more or less severe epidermal detachment presenting as blisters and areas of denuded skin. Currently, TEN and SJS are considered to be two ends of a spectrum of severe epidermolytic adverse cutaneous drug reactions, differing only by their extent of skin detachment. Drugs are assumed or identified as the main cause of SJS/TEN in most cases, but Mycoplasma pneumoniae and Herpes simplex virus infections are well documented causes alongside rare cases in which the aetiology remains unknown. Several drugs are at "high" risk of inducing TEN/SJS including: Allopurinol, Trimethoprim-sulfamethoxazole and other sulfonamide-antibiotics, aminopenicillins, cephalosporins, quinolones, carbamazepine, phenytoin, phenobarbital and NSAID's of the oxicam-type. Genetic susceptibility to SJS and TEN is likely as exemplified by the strong association observed in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and SJS induced by carbamazepine. Diagnosis relies mainly on clinical signs together with the histological analysis of a skin biopsy showing typical full-thickness epidermal necrolysis due to extensive keratinocyte apoptosis. Differential diagnosis includes linear IgA dermatosis and paraneoplastic pemphigus, pemphigus vulgaris and bullous pemphigoid, acute generalized exanthematous pustulosis (AGEP), disseminated fixed bullous drug eruption and staphyloccocal scalded skin syndrome (SSSS). Due to the high risk of mortality, management of patients with SJS/TEN requires rapid diagnosis, evaluation of the prognosis using SCORTEN, identification and interruption of the culprit drug, specialized supportive care ideally in an intensive care unit, and consideration of immunomodulating agents such as high-dose intravenous immunoglobulin therapy. SJS and TEN are severe and life-threatening. The average reported mortality rate of SJS is 1-5%, and of TEN is 25-35%; it can be even higher in elderly patients and those with a large surface area of epidermal detachment. More than 50% of patients surviving TEN suffer from long-term sequelae of the disease

Isoenzyme der α-Amylase im Serum von Patienten mit Cystischer Fibröse

Bei 34 Patienten mit Cystischer Fibröse wurden die Isoenzyme der a-Amylase (a-l,4-Glucan 4-Glucanohydrolase, EC 3.2.1.1) im Serum mikroelektrophoretisch aufgetrennt und mit dem Isoamylasemustervon 14 gesunden Kontrpllpersonen verglichen. Folgende Befunde wurden erhoben: 1. Im Serum von Patienten mit Cystischer Fibröse konnte 13 mal nur Pankreasamylase, 17 mal nur Speichelamylase nachgewiesen werden. 4 mal fand sich sowohl Speichel- als auch Pankreasamylase im Serum. 2. Bei gesunden Kontrollpersonen wurde 12 mal Speichel- und Pankreasamylase im Serum gefunden, 2 mal nur Pankreasisoamylase. 3. Unter Berücksichtigung der Literatur wird das häufige Fehlen von Pankreasamylase im Serum von Patienten mit Cystischer Fibröse als Ausdruck einer verminderten Pankreasfunktion gedeutet.Peer Reviewe